Topic: cellular pathway

Kymera Therapeutics

Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.

Dewpoint Therapeutics

Dewpoint Therapeutics is on a mission to develop a drug platform that targets biomolecular condensates, an understudied type of organelle found inside cells, and potentially target any and all diseases.

Casma Therapeutics

After a couple of years’ incubation at Third Rock, Casma Therapeutics launched in May 2018 with $58.5 million to create treatments aimed at autophagy, or the cell’s garbage disposal.